Association Between Hormone Replacement Therapy and Development of Endometrial Cancer: Results From a Prospective US Cohort Study
Authors:
Open Access
- 17 January 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8, 802959
Abstract
Although hormone replacement therapy (HRT) use is associated with elevated endometrial cancer(EC) risk, little evidence assesses potential effect-modifiers on HRT-related EC in a long-term follow-up. In this large-scale longitudinal cohort study, we tried to evaluate the association between different HRT types/methods use and risk of EC, and reveal this risk within different body mass index (BMI) groups. In whole cohort, 677 EC occurred during mean 11.6 years follow-up. Cox proportional hazards regression was used to estimate multivariable-adjusted hazards ratios (HRs) and 95% confidence intervals (CIs) with HRT status (never, former, or current) for risk of EC incidence. Current HRT use was not significantly associated with EC risk (HR for current vs. never HRT use: 1.13; 95% CI: 0.92, 1.38) in the whole cohort, but presented a dose-response effect on increased EC risk (HR for >10-year use vs. never HRT use: 1.73; 95% CI: 1.35, 2.21). Moreover, EC risk differed in distinct regimens or subsets (all Pinteraction < 0.05). Estrogen-only use was associated with elevated EC risk (HR for current vs. never HRT use: 1.51; 95% CI: 1.12, 2.04), but women with high BMI (> 30 kg/m2) who currently use estrogen-only harbored decreased EC risk (HR: 0.56; 95% CI: 0.38, 0.82) compared to counterparts without HRT use. Estrogen-only use is associated with increased EC risk, and precise monitoring of EC development for postmenopausal women with long-term HRT use are urgently needed. BMI could serve as an important surrogate to assess this risk.Keywords
This publication has 41 references indexed in Scilit:
- Interplay of adipokines and myokines in cancer pathophysiology: Emerging therapeutic implicationsWorld Journal of Experimental Medicine, 2013
- Progesterone: the ultimate endometrial tumor suppressorTrends in Endocrinology & Metabolism, 2011
- Body Mass Index, Hormone Replacement Therapy, and Endometrial Cancer Risk: A Meta-AnalysisCancer Epidemiology, Biomarkers & Prevention, 2010
- Menopausal Hormone Therapy and Risk of Endometrial Carcinoma Among Postmenopausal Women in the European Prospective Investigation into Cancer and NutritionAmerican Journal of Epidemiology, 2010
- Long-term Postmenopausal Hormone Therapy and Endometrial CancerCancer Epidemiology, Biomarkers & Prevention, 2010
- The Second World Cancer Research Fund/American Institute for Cancer Research Expert Report. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global PerspectiveProceedings of the Nutrition Society, 2008
- Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studiesThe Lancet, 2008
- Endometrial Carcinoma Risks among Menopausal Estrogen plus Progestin and Unopposed Estrogen Users in a Cohort of Postmenopausal WomenCancer Epidemiology, Biomarkers & Prevention, 2005
- Overweight, obesity and cancer: epidemiological evidence and proposed mechanismsNature Reviews Cancer, 2004
- Chi-squared goodness-of-fit tests for the proportional hazards regression modelBiometrika, 1980